CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 68 enrolled
Drug / intervention
EnligHTN™ Renal Denervation Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02006758
NCT02006758N/ACompleted
CompareCT.gov

EnligHTN European Observational Study

Abbott Medical Devices·observational·Posted Dec 10, 2013·Updated Oct 16, 2019

In Brief

An observational study evaluating EnligHTN™ Renal Denervation System for Uncontrolled Hypertension. Completed, enrolled 68 participants across 13 sites in 6 countries.

Detailed Summary

The purpose of this observational study is to further evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of participants with uncontrolled hypertension in clinical routine practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUncontrolled Hypertension
CountriesBelgium, Estonia, Italy, Portugal, Spain, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 10, 2013
Enrollment StartNov 1, 2013
Primary CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 12.6 years ago

Interventions

EnligHTN™ Renal Denervation Systemdevice

The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).